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In this article we detail the kinetic changes that take place in the expression of
immunologically important cell surface molecules by lymph-borne cells during in
vivo immune responses and describe the consequences of these changes for the im-
munological functions of these cells . We used the unique advantages of the cannu-
lated lymphatic model in the sheep (1) to integrate the physiological changes occur-
ring in antigen-stimulated lymphoid tissue withlymph cell function . This experimental
modelhas thepotential to provide informationonlymphoid and accessory cell func-
tion that is not readily gained with other systems . The approaches we have used
involve the development of mAbs to molecules associated with immune cell func-
tion, theuseofthese monoclonals to measure thechanges inimmune cell phenotype
that occur during in vivo immune responses, and correlation of these changes with
alteration of in vitro immunological functions of afferent lymph dendritic cells
(DC). '
The major advantage of the cannulated lymphatic model lies in the opportunity
to access in vivo fractionated cell populations from distinct lymphoid compartments .
To do this, the afferent lymphatics to, and the efferent lymphatics from single pe-
ripheral lymph nodes are cannulated and lymph is collected quantitatively over ex-
tended periods of time (often 3-4 wk) .
The cellular constituents of afferent lymph and efferent lymph are different (2) .
Afferent lymph contains few cells (0.5-1 x 106/ml) but does include between 1 and
10% dendritic cells and <l0olo B cells . Efferent lymph contains 5-10-foldmore cells,
consisting of-3017o B cells and 70% T cells (3) . No cells of the macrophage/mono-
cyte orDC series occur in efferent lymph . Evidence for thiscomes from morpholog-
ical observation (2) as well as from data that show that efferent cells are incapable
of responding to soluble antigen in vitro without the addition of accessory cells (4) .
Experiments described in a companion paper (5) demonstrated that DC isolated
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from sheep afferent lymph are able to associate with antigen injected in vivo and
to present that antigen to antigen-specific T cells. Furthermore, they seem to have
a unique role in the induction of primary immune responses (6). In afferent lymph
thesecells can be defined as those with dendritic morphology that constitutively ex-
press MHC class II and CD1 (5, 7). The major biological function of class II is
known to be the binding of antigenic peptides and communication with the TCR
(8) and CD4 (9) molecules on T helper/inducer populations.
The CDl family of molecules is expressed mainly by cortical thymocytes, B cells,
and dendritic cells in several sites (10). Within the thymus CD1 is thought to be
covalently associated with the CD8 molecule and it is speculated to be involved in
T cell selection (11). The function ofCDl expressed on DC is at present unknown.
We document the alteration of MHC class II and CD1 expression by dendritic
cells in sheep afferent lymph draining sites of both primary and secondary in vivo
antigen challenge. Using in vitro MLR and soluble antigen-induced proliferation
(ofantigen-specific T cell lines) assays we have studied the accessory function ofthese
cells isolated at intervals during immune responses. Increased accessory function
ofDC correlates both temporally and quantitatively with MHC class II expression
but not CDl.
Materials and Methods
Animals and Surgery.
￿
1-yr-old blackface x firm crossbred sheep were obtained from IAGPR,
Dryden, UK. Sheep were primed by intradermal injection of five human doses of Bacillus
Calmette Guerin (BCG; Glaxo, Greenford, UK) and intramuscular injection of 1 mg OVA
or sperm whalemyoglobin (both Sigma Chemical Co., Poole, UK) in CFA. Prefemoral afferent
(peripheral) lymph was collected by the ablation of the prefemoral lymph node and cannula-
tion of the efferent duct 6 wk later(3). This duct now contains afferent lymph and is known
as a " pseudoafferent." Efferent lymph was collected by the chronic carnulation ofthe popliteal
efferent duct (12). This procedure is necessary because the yields from standard afferent lym-
phatic cannulations are always very low. Animals were allowed at least 7 d postoperative recovery
before the startofthe experiments. Lymph was collected quantitatively in sterile (siliconized)
bottles containing heparin.
Cell Fractionation.
￿
Afferent lymph cells were fractionated into lymphocytes and dendritic
cells by centrifugation over stepped metrizamide (Nygaard & Co., Oslo, Norway) gradients
(13). Purity of fractionation was always assessed by staining with the monoclonal anti-sheep
CDl antibody, VPM 5 (5), as well as by using geimsa-stained cytospin smears. B and T cells
were enumerated using FITC-conjugated mAbs to sheep X light chains (VPM 8) and the
sheep analogue ofCD5, SBUTl (7). Efferent lymph T cells were isolated by nylon-wool (Type
200; Fenwall Laboratories, Deerfield, IL) fractionation (14).
Flow Cytometry.
￿
Class II and CDl quantitation by flow cytometry was done usingsingle
batches of FITC-conjugated SW73 .2 or VPM 5 at 10 ttg/ml in HBSSd0.1% BSA/0.01 M so-
dium azide. F(ab')2 of SW73.2 and IgM of VPM 5 were coupled to FITC at a wt/wt ratio
of 100:1, protein/FITC). SW73 .2 is a rat mAb specific for a nonpolymorphic determinant
on sheep class II that reacts with the known products of all the expressed class II loci (15).
106 cells of each cell population (afferent lymph dendritic cells and lymphocytes) were stained
daily with 50 pl FITC-antibody. After a 30-min incubation at 4°C the cells were spun through
0.5 ml FCS, washed once, made to 0.5 ml with HBSS + 5o7o FCS, then fixed by the addition
of 0.5 ml 15o' paraformaldehyde. Daily samples were stored at 40C for analysis at the end
of the experiment. 104 cells were analyzed by flow cytometry using a Becton Dickenson &
Co. (Mountain View, CA) FACS IV with a 488-nm argon laser. FITC (520 nm) emission
was detected with the photomultiplier tube voltage set at 555 mV. Forward and side (90°)
scatter amplification was linear, while FITC amplification was logarithmic (all 256 channels).
Antibody-negative cells were gated by reference to fixed cell samples reacted with a negativeHOPKINS ET AL.
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mAb. Within experiments, class II-positive controls were made by the daily staining of 2 x
105 BL20 cells, a cloned bovine leukosis cell line (16). In all experiments BL20 had a modal
channel number of 180 (178-186) when stained with FITC-SW73.2 as detailed above. The
data are expressed as relative fluorescence intensity (modal channel number). The cell cycle
state of the cells was assessed by using propidium iodide (PI; Sigma) using the methods of
Vindelov et al. (17). Cell couplets were gated out by using resting efferent lymph cells as
the control.
Saturation Binding Studies.
￿
The quantitation of anti-class II antibody binding sites per cell
was by saturation binding as described previously (15, 18). Briefly, washed cells were made
to 2 x 106/ml in RPMI 1640 + 10% FCS + 0.01 M sodium azide. 250 Etl of cell suspen-
sion were mixed with doubling dilutions of '25I- (Radiochemical Centre, Amersham, UK)
labeled Fab' SW73.2 at 4°C. After a 2-h incubation, aliquots of the reaction mixture from
each dilution were layered on to 200 141 phthalate (dibutyl/dionyl phthalate at a ratio of 4:1)
in 0.4 ml microfuge tubes and centrifuged at 13,000 g for 5 min then snap frozen in liquid
N2. The frozen microfuge tubes were then cut in order to separate the radioactivity associated
with the cells from the unbound antibody. As with the flow cytometry experiments, these
studies were controlled daily by measurements on the BL20 cell line (mean of 2 x 105 anti-
body binding sites per cell, variation 1.6-2.3 x 105). The proportion ofclass II-positive cells
in each population was always consideredwhen calculating the number of antibody binding
sites per cell.
Purification ofMonoclonal Ig
￿
IgM fromVPM5 ascitic fluid (and ofthe mouse IgM anti-sheep
classII mAb VPM 3) was purified by initial precipitation with ammonium sulphate at 45,70
saturation and then gel filtration using Sephacryl S300 (Pharmacia Fine Chemicals, Piscataway,
NJ). IgG2a and F(ab')2 isolation from SW73 .2 ascitic fluid were as described previously (15).
The Fab' fragment was produced from the F(aV)2 by reduction (10 mM dithiothreitol in 100
mM Tris, pH 8, for 1 h) and alkylation (30 mM iodoacetamide for 1 h). The F(ab')2 was
purified on DEAE-cellulose (10 mM phosphate buffer, pH 7.5). The Fab' fragment was purified
by gel filtration on Sephadex G200 superfine (Pharmacia Fine Chemicals). Purified Ig of
VPM 5 and F(ab')2 of SW73.2 for the proliferation assays was made to 100 t~g/ml in RPMI
1640 + 10% FCS before sterile filtration and storage at -70°C. Supernatants of an IgM
anti-sheep class II (VPM 3), the anti-sheep CDl monoclonal SBUT6 (7) and the anti-bo-
vine CDl antibodies CC13 and CC14 (19) used in the irk vitro assays were dialyzed against
RPMI 1640, filter sterilized, then FCS was added to 10%.
ProductionofAntigen-specific CellLines.
￿
Cell lines specific for the antigens OVA and purified
protein derivative oftuberculin (PPD) were constructed as described by Bujdoso et al. (20).
Briefly, efferent lymphocytes were cultured at 2 x 106/ml in 24-well culture plates with RPMI
1640 + l0o7o FCS containing either OVA or PPD at 25 kg/ml. Irradiated PBM were added
to 5 x 105/ml. After 7 d incubation, viable cells were harvested by LYMPHOPREP and fur-
ther incubated for 14 d at 1 x 105/ml with 20 U human rIL-2 (a gift from Biogen SA, Basel,
Switzerland) added every 3 d. Viable cells were again harvested and restimulated with an-
tigen by culturing at 5 x 105 cells/ml with 1 x 106/ml irradiated, autologous PBM. After
7 d the cells were again harvested and expanded with IL-2 for 14 d. The viable cells were
then cryopreserved in liquid N2 using a programmed cell freezer (Planar Products Ltd.,
London, UK).
In Vitro Proliferation Assays.
￿
Briefly, 104 antigen-specific T cells per well (in round-bottomed
microtest trays; Gibco-Biocult, Paisley, Scotland) were cultured with OVA, sperm whale myo-
globin (both Sigma Chemical Co.) or PPD (batch 297; Central Veterinary Laboratories,
Weybridge, UK) at a final concentration of25,ug/ml. APCs for soluble antigen-induced lym-
phocyte proliferation and MLR assays were 1 x 103 to 2.5 x 104 PBMC or afferent lymph
DC irradiated with 3,000 rad -f-irradiation. PBMC were prepared by centrifugation over LYM-
PHOPREP (Nygaard). Responder cells in MLR assays were 2.5 x 104 allogeneic efferent
lymph T cells purified by nylon-wool.
The effects of monoclonal anti-class II and anti-CD1 antibodies on in vitro proliferation
and MLR assays were assessed by the addition of 20 p,l of SW73.2 and VPM 5 at dilutions
of 0.01-100 Wg/ml. Supernatants of VPM 3, SBUT6, CC13, and CC14 were used at final
concentrations of 1/2, 1/5, and 1/10.1306
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Experimental Protocol.
￿
A prefemoral "pseudoafferent" lymphatic was cannulated and 7 d
laterantigen was introduced into the drainage area by intradermal injection of 50 kg PPD,
OVA, or -sperm whale myoglobin. Daily for 2 d before and for 8 d after in vivo antigenic
challenge in both antigen-naive and in antigen-primed animals the levels of both MHC class
Il and CDl expression by the purified DC were assessed by flow cytometry Quantitative
expression of class II expression was also measured by a saturation binding technique. The
immunological function of the DC was assessed by testing their ability to present soluble
antigen (either OVA or PPD) to autologous OVA-specific or PPD-specific T cell lines and
to stimulate allogenic efferent T cells in an MLR. The involvement of MHC class II and
CDl in the alterations in DC function was studied by examining the effects ofmAbs to these
molecules in these in vitro assays. 11 sheep were used (four with PPD and four with OVA
and three with sperm whale myoglobin) to assess secondary antigenic challenge; while six
(two for each antigen) sheep were used to compare the primary and secondary responses.
Results
Effect ofIn Vivo Antigenic Challenge on Afferent Cell Output.
￿
The changes in the per-
centage of class II-positive lymphocytes in afferent lymph during a secondary im-
mune response to PPD can be seen in Fig. 1 a . The proportion of s1g" cells remains
unaltered at N9% (6-12%) of the total, but class II-expressing T cellsincrease from
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ti28% of the total (variation 23-35%) up to 54% (45-59%). The proportion of
CD1+ DC (1-10%) and macrophages (<0.2%) within individual animals remains
stable throughout the response. The results obtained with OVAandmyoglobinwere
the same as those with PPD.
Local antigenic stimulation also induces changes in lymph cell kinetics (Fig. 1
b). Resting afferent lymph has a total cell output of between 6 and 10 x 106 cells/h,
this falls three- to fivefold, to <2 x 106/h during days 1-3 because of adrop in lymph
cell concentration. By day 5 the cell output increases >5-fold (to 5-8 x 107/h), partly
because of arise in lymph fluid flow rate. Thesechanges are only transient however,
as by 8-9 d afterchallenge thelymph cell phenotypeandkinetics are similar to those
in resting lymph. These changes are restricted to secondary responses. No detect-
able modulation of class II expression and cell kinetics occur during primary anti-
genic challenge in antigen-naive sheep.
Alteration in Afferent DC Expression of Class H.
￿
The rise in the proportion of class
II-positive cells in afferent lymph during secondary responses is also accompanied
by marked increases in the overall level of class II expression by single cells. Anti-
body binding studies have shown that DC constitutively express N3 x 105 MHC
class II molecules percell (assumingoneantibody bindingsite perclassII molecule)
(variation between 2.3 and 3.6 x 105), which doubles to N6 x 105 on day 3, and
increases almost sixfold to 1.7 x 106 (1.5-2 .1 x 106) in response to in vivo challenge
with antigen (Fig. 2 a). These figures were calculated by saturation binding, where
1 x 106 DC were reacted with dilutions of 1251-labeled F(ab')2 SW73 .2, 1 /Ag anti-
body is 150,000 cpm. 1 x 106 DC from day 0 afferent labeled with 7,000 cpm at
saturation (i.e., 3 x 105 molecules per cell), on day 3 they labeled with 15,000 cpm
at saturation (6 x 105 molecules per cell), and on day 5 with 41,000 cpm at satura-
tion (1.7 x 106 molecules per cell). Cellular class II expression by lymphocytes is
also increased, rising from a mean resting level of <1 x 105 (0.5-1 .3 x 105) up to
2.3 x 105 (1 .6-2.6 x 105). These alterations are only transient, however (Fig. 2 b),
as quantitative class II expression of afferent cells returns to resting levels by day
8 after challenge.
An exact parallel series of experiments has been done to monitor the changes,
in terms of both cell output and class II expression, in the primaryresponse. Using
sperm whale myoglobin as antigen and repeatingthe experiments as described above
we were unable to demonstrate any significant alteration in either cell number or
MHC class II expression. In contrast, subsequent secondary challenge with myo-
globin in the same animalsgave identical resultsas those describedforOVA andPPD.
Flow cytometry confirms thesedata (Fig. 3). DC from unstimulated lymph (time
0) have a log relative fluorescence intensity (modal channel number, MCN) of 196
(190-205); this increases to MCN of 255 (>250 in all of 10 experiments) on days
4 and 5 after in vivo challenge, and returns to 194 (190-202) on day 8. The class
II-positive lymphocytes from unstimulated lymph have a MCN of 133 (125-138),
which increases to 164(159-170) days 4 after antigen (data not shown). An increase
of 30 channels represents a doubling of fluorescence intensity, therefore the rise in
MCN of DC from 196 (on day 0) to >250 (on day 5) represents at least a fourfold
increase in class II expression.
Alteration in Afferent DC Expression ofCDI.
￿
CDl expression by DC in resting afferent
lymph show a single population (time 0) with a MCN of 187 (variation between1308
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179 and 196 in five experiments). Antigenic stimulation ofan antigen-naive animal
(primary stimulation)resultsin theappearanceofthree distinct CDl expressingpopu-
lations ofDC at the 14-h time point (Fig. 4). The dull staining population consists
of15-20% ofDC, with MCNof183(175-188); theintermediatepopulation of52-60%
has MCN of205 (201-209) and the bright population of 15-20% with MCN of233
(228-239). The alteration in CDl expression is onlytransient asthe flow cytometry
profile by 45 h is identical to that at time 0.
In contrast, changes inCD1 expression afterantigenic challenge in a primed sheep
(secondary stimulation) are far less transient and show the appearance ofthe inter-
mediate CDl expressing population with MCN of 207 (197-214) from 2-6 d after
antigen inoculation (data not shown). Although the DC have distinct levels ofCDl
expression (after both primary andsecondarychallenge), they have a homogeneous
expression of class II and cannot be distinguished by their 90° scatter profile (sideHOPKINS ET AL .
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FIGURE 3 .
￿
Flow cytometry analysis of purified afferent lymph DC isolated at daily intervals
after secondary in vivo antigenic stimulation . Each panel shows a fluorescence histogram ofDC
stained with FITC-SW 73 .2 (anti-sheep class II) . The figures represent themodal channel number
(MCN) ofthe antibody-positive cell population . 520 nm emitted light was detected with PMT
set at 555 mV amplification was logarithmic (256 channels) .
scatter) . The increase in class II expression during secondary challenge occurs with
every cell and not on minor populations .
By coupling mAb staining with cell cycle analysis it is possible to correlate cell
surfacephenotype with stages ofcell activation . Staining with PI andthemonoclonals
SW73.2 (anti-class II) andVPM 5 (anti-CDI) showed that the increase in DC class
II expression and change in CDl phenotype was not associated with these cells en-
tering cell cycle (data not shown) .
Alteration in theIn Vitro Accessory Function ofDC as aResult ofIn Vivo Antigenic Stimula-
tion . In the companion article (5) we have reported that in vivo pulsed afferent
DC are capable of stimulating autologous T cell lines, in the absence of exogenous
antigen, in an antigen-specific manner. In this article we investigate their accessory
potential in the presence ofexogenous antigen . DC fractionated from afferent lymph
were tested both before, and at daily intervals after, in vivo antigenic challenge to
see whether their antigen-presenting ability was altered and if such alteration cor-
related with changes in the expression of either CD1 or MHC class II . Antigen-
induced proliferation ofPPD- and OVA-specific T cell lines and MLR assays were
used to assess the in vitro antigen-presenting function of theDC . In all these experi-
ments irradiatedPBMC were used as acontrol forfractionated DC . Representative
data from these experiments are shown in Figs . 5 and 6.
Fig . 5 compares the effects of in vivo primary and in vivo secondary antigenic
challenge (to spermwhale myoglobin) on the abilityofDC, isolated at different times
after immune stimulation, to present alloantigen to allogeneic T cells and OVA to
an OVA-specific T cell line. The same sheep were used for both the primary and
secondary experiments and before the start ofthe secondary responses the animals1310
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FIGURE 4.
￿
Flow cytometry dot plots (linear side
[90° ] scatter vs. logio fluorescence intensity) of
afferent lymph DC stained with the anti-sheep
CD1 mAbVPM 5 . Cells are taken at intervals
after primary antigenic challenge in an antigen-
naive animal .
were primed with, and shown to be responsive to, spermwhale myoglobin . It is clear
from thesedata that the capacity to induceT cell proliferation byDC isolated during
the in vivo primary responses does not vary significantly after antigen inoculation .
In contrast is the effect of secondary in vivo challenge . Although the results with
PBMC are unchanging, the proliferation of theT cell lines and allogeneic efferent
cells cultured with DC is markedly increased in both the antigen-induced prolifera-
tion and MLR assays respectively .
Fig . 6 further illustratesthe abilityofDC from in vivo stimulated afferent lymph,
isolated during asecondary response to myoglobin, to stimulate inanMLR or OVA-
inducedproliferation assay. It is clear that DC induce a substantially greater prolifer-
ation than PBM, which is most noticeable at limiting accessory cell concentrations .
1 x 10 3 DC, isolated 4 and 5 d after in vivo challenge with myoglobin, supportHOPKINS ET AL.
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FIGURE 5 .
￿
Comparison of the accessory function of afferent lymph DC and PBMC isolated
at daily intervals after in vivo primary ofin vivo secondary antigenic challenge with sperm whale
myoglobin . Response of 2.5 x 10 4 efferent lymphocytes in MLR assays (a and b); and 1 x 104
OVA-specific T cells OVA-induced proliferation assays (c and d). 1 x 104 accessory cells were
used in both assay systems .
18-20,000 cpm (MLR) and 15-16,000 cpm(OVA) proliferation, approximately fivefold
greaterthan that initiated byDC from resting lymph (4,000 and 3,000 cpm, respec-
tively) . Thatnumber ofPBMdidnot induce proliferation in either assay. The modu-
lation ofproliferationinduced by DC correlates temporally with the differential ex-
pression ofMHC class II and not CDl . The relative degree of in vitro function
gradually declines to preinoculation levels by day 8 . Identical results were obtained
when PPD and OVA were used as the in vivo antigen and also when autologous
efferent lymphocytes were used as responder cells in the antigen-induced prolifera-
tion assays . These data support the view that DC, activated during secondary anti-
genic challenge, have an increased capacity to present exogenous antigen .
Effect ofMonoclonalAnti-Class IIandAnti-CDI Monoclonals on In KimDCFunction .
￿
To
assess the role of class II and CDl expression on the antigen-presenting function1312
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FIGURE 6 .
￿
Response of2.5 x 10 4 efferent lymphocytes in MLR assays ; and 1 x 104 OVA-specific
T cells in OVA-induced proliferation assays. Titration ofPBM and afferent lymph DC isolated
at intervals after in vivo challenge with myoglobin in amyoglobin-primed sheep (secondary im-
mune response) .
of afferent lymph DC, titrations of purified Ig [or F(ab')2 of SW73.2] of the
anti-class II and anti-CD1 monoclonals were added to the in vitro assays . The
anti-class Il antibodies tested, SW73 .2 (IgG2a)andVPM 3 (IgM), totally inhibited
lymphocyte proliferationin both assays, with DC taken from resting afferent lymph .HOPKINS ET AL.
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The enhanced proliferation found with the use of DC isolated at days 3, 5, and 8
after secondary antigenic challengewasalso blocked. SW73.2 andVPM 3 gave50%
inhibition at 10 ng/ml, and at a 1/10 dilution, respectively, with 100% inhibition
at 10 Ag and at a 1/2 dilution (data not shown). The addition ofthe anti-CD1 anti-
bodies VPM 5, SBUT6, CC13, andCC14 had noeffect at any time on either assay,
even with supernatant dilutions as high as 1/2.
Discussion
In this article we examine the kinetic changes in afferent lymph cell output and
phenotype that occur as a result ofin vivo primary and in vivo secondary antigenic
stimulation in thedrainage areaofthe afferent lymphatic, andcorrelatethese changes
with alterations in in vitro immunological function ofafferent lymph DC. Afferent
lymph DC are defined as those cells ofdendritic morphology that constitutively ex-
press both MHC class II and the sheep analogue of CD1 (5).
Primary antigenic challenge stimulates no detectable alterations in afferent cell
output or the numbers ofcells expressing sIg, class II, or CDI, although dramatic
changes occur in levels of CD1 expression by a large majority of individual DC.
Restingafferent lymph has a relatively homogeneous population ofCD1+ DC with
a MCN of 187. Within 14 h ofprimary challenge up to 60% DC express 1.5 times
the number ofCD1 molecules (MCN of 205) and 15-20% express almost 3 times
the level (MCN of233). These changes are very transient however, as by 45 h the
pattern in resting lymph is re-established.
In contrast are the changes that occurduring secondary responses. Although the
relative proportions of the different cell populations (DC, B cells, and T cells) re-
main stable, the total cell output is decreased on days 1-3 afterchallenge but is in-
creased to approximatelyfivefold preinoculationlevels on days 4-7. In addition, the
proportion ofclass II-positive cells increases, resulting in a more than doubling of
the proportion ofclass II-positive cells at days 4-5. This results from a rise in the
number ofclass II-positive T cells as there is no change in the proportion of DC
and B cells in afferent lymph. Unlike the primary response, no immediate effect
on CD1 expression is seen, but the intermediate MI-expressing population (MCN
207) appears by day 2, reaching up to 35% on day 5 and disappearing after day 7.
In vivo antigenic stimulation in primed animals was demonstrated to have pro-
found effects on the quantitative expression ofMHC class II, as well as CD1. Ifwe
assume one antibody binding site per class II molecule, the expression of class II
on DC is increased from 3 x 105 molecules (channel number 196) to 1.7 x 106 mol-
ecules (channel number >250) per cell as a result ofantigenic challenge. This level
ofclass II expression by sheep DC and its relative increase induced by exogenous
stimuli are very similar to those shown for mouse epidermal Langerhans' cells (21)
which seem to be the precursors oflymphoid DC (22). Changes in class II expres-
sion by afferent lymphocytes are less marked, increasing from -1 x 105 (channel
number 133) to 2 x 105 (channel number 164). These dataestablish thatthe stimuli
for the increase in class II occur in antigenically primed animalsonly. This strongly
suggests that they arise from antigen-activated Tcells. Cytokines from activated T
cells have been shown to induce class II synthesis (23). Candidate mediators there-
forewould includeBSF1/IL-4 and IFN-,y, both ofwhichhave been showntoinduce
class II expression in nondividing cells(24-27). It is ofinterest tonote that the rela-1314
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tive increase in class II expression by DC ( x 5-6) is much greater than for afferent
lymphocytes (x 2). This raises the possibility that the class II expressed by DC and
lymphocytepopulations arequalitativelydifferent. Afferent Tcellsfor instance could
be restricted in their expression ofindividuallocus products. The alternative expla-
nation, that the increase in class II expression is a result of cell division (28), has
been eliminated, as we have shown that the afferent lymph DC are not in cycle.
There have been no previous descriptions ofquantitative variations ofCD1 expres-
sion; the stimuli for the changes in CD1 expression are, therefore, open to specula-
tion. The data inthisarticleillustrate that afferent lymph DC ofthe sheep, likethose
ofthe rat (29), rabbit (30), pig (31), and bovine (32), can present soluble antigen
to antigen-specific Tcells as well as stimulating allogeneic lymphocytes in the pri-
mary MLR. The capacity ofafferent DC to enhance in vitro lymphocyte prolifera-
tion seems also to correlate directly with increased class II expression but not with
CD1. At day 5 after in vivo antigen, the DC express five- to sixfold the preinocula-
tion levels ofclass II and, at limiting DC concentrations, areabout fivefold as active
in the proliferation assays. The main increase in dendritic cell expression ofCD1
occurs byday 2, before any increase in class II and enhancement ofantigen presen-
tation. In addition, treatment ofthe cells with anti-class II antibodies, butnot anti-
CD1 antibodies, abrogatesall in vitro accessory function, includingthat at thepeak
of the in vivo response.
Although class II expression is necessary for antigen presentation (33, 34) and
cells such as macrophages and astrocytes can present antigen only after they have
been induced to expressclassII (35, 36), it is beginningto be clear that quantitative
variation of expressed class II plays a central role in immune regulation (37-40)
and aberrant expression may contribute to autoimmune disease (41). These data
support the proposition that themagnitudeofT cell responses isrelatedtothe product
of the concentrations ofantigen and class II (42). The function ofCD1 expressed
byDC is unclear, but in view ofits differential expression during both primary and
secondary responses, as well as its homology with both MHC class I and class II
(43), it is intriguing to speculate on its potential as an antigen-binding protein. In
this article we document a temporal correlation between enhanced accessory func-
tion of DC and increases in class II expression, but antigenic stimulation almost
certainly affects parameters other than CD1 andclassII synthesis. IL-1, forinstance,
is produced as aresult ofmany different stimuli(44) andhasbeen shown to upregu-
late the stimulatory activity of DC (45). In vivo stimulation could induce DC to
secrete IL-1 or even express membrane IL-1 on the cell surface (46). The results
could also be explained by the fact thatthe enhancedcapacity toinduce a prolifera-
tive response in lymphocytes is mediated by IL-1 or similar molecules released by
in vivo activated DC.
In summary, wedescribe in this articleour approach to the studyofthe molecules
associated with immune cell function. We describe the in vivovariation ofCD1 and
class II expression by DC, implicating quantitative variations of class II expression
in immune regulationinvivo. Wealsoextend ourknowledge to include thoseevents
that occur within the relevant physiological environment in vivo. Furtherworkwill
concentrate onthe differential expression ofthe productsofthe individualCD1 and
class 11 genes by the distinct cell populations within the sheep lymphoid system.HOPKINS ET AL.
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Summary
The experiments described in this article characterize the phenotypic and func-
tional changes in afferent lymph cell populations that occur as a result of in vivo
immune stimulation. During theprimaryimmune response (in antigen-naivesheep)
there are very transient increases in level of CDl expression by subpopulations of
dendritic cells (DC) but no alterations in cell kinetics or MHC class II expression.
In contrast, secondary antigenicchallenge (in primed sheep) into the drainage area
of an afferent lymphatic causes profound changes in the cell output, characterized
by a greaterthan threefold drop in total cell output on days 1-3 followed by an ap-
proximate fivefold rise on day 5. There is also a substantial increase in both the
proportion of MHC class II-positive T lymphocytes (from 28 to 54%) and in the
quantitative expression ofclass II by both DC and lymphocytes. Class II expression
by DC increases five- to sixfold by day 5, while the level of expression of class II
on lymphocytes approximately doubles. The increase in CDl expression during the
secondary response is more prolonged than during the primary response, beingde-
tectable between days 2 and 6 after challenge. The rise in class II affects the whole
DC population, in contrast to CD1 where the increase affects only a subpopulation
of cells.
In terms of functional properties, afferent lymph DC isolated during a primary
response show no alteration oftheir activity,whereasDC taken 4-5 d aftersecondary
challenge are up to fivefold more active in their ability to present soluble antigen
to primed autologous Tcellsand to antigen-specific cell lines as well as to stimulate
in the MLR. The relative expression of class II correlates temporally with an in-
creased capacity of DC to present antigen. Monoclonal anti-class II antibodies to-
tally inhibit the in vitro assays but anti-CD1 antibodies have no effect. The previous
paper(5) has demonstrated that afferent DC can associate with antigen in vivo and
can present that antigen to antigen-specific T cells. This article extends our knowl-
edge of DC biology and demonstrates that DC, activated during secondary in vivo
immune responses, have an enhanced ability to present an antigen, unrelated to
that used for challenge, to specific Tcell lines. This enhancementcorrelates directly
with quantitative variation of expressed class II and not CDl and suggests that this
variation in class II expression plays aphysiological role in in vivo immune regulation.
Receivedfor publication 6 March 1989 and in revisedform 15 June 1989.
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